Table 2 Demographic and clinical characteristics of health controls and schizophrenia patients with and without tardive dyskinesia
From: Altered DNA methylation of CYP2E1 gene in schizophrenia patients with tardive dyskinesia
Variables | HC group (n = 35) | NTD group (n = 35) | TD group (n = 35) | F / χ2 / t | p |
|---|---|---|---|---|---|
Age (years) | 44.4 ± 11.6a | 44.9 ± 11.3 | 45.1 ± 12.3 | 0.03 | 0.968 |
Education (years) | 12.0 ± 3.1 | 11.4 ± 2.9 | 10.3 ± 2.7 | 3.09 | 0.051 |
Sex (male/female) | 20/15 | 20/15 | 20/15 | 0 | 1.000 |
PANSS score Total (PANSST) | – | 67.1 ± 16.0 | 75.6 ± 16.2 | 2.13 | 0.037 |
Positive (PANSSP) | – | 17.5 ± 6.8 | 19.4 ± 6.1 | 1.19 | 0.240 |
Negative (PANSSN) | – | 17.8 ± 6.5 | 22.2 ± 7.0 | 2.60 | 0.012 |
General psychopathology (PANSSG) | – | 30.6 ± 8.4 | 33.9 ± 7.0 | 1.75 | 0.086 |
AIMS total score | – | – | 14.6 ± 5.8 | – | – |
Duration of disease (years) |  | 21.5 ± 12.1 | 21.1 ± 11.3 | − 0.14 | 0.887 |
Current medication time (months) | – | 30 (98) | 30 (132) | − 0.79 | 0.428 |
Medication types (atypical/typical antipsychotics) | – | 30/5 | 32/3 | 0.57 | 0.452 |